<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04536467</url>
  </required_header>
  <id_info>
    <org_study_id>FWA 00015574</org_study_id>
    <nct_id>NCT04536467</nct_id>
  </id_info>
  <brief_title>Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients</brief_title>
  <official_title>Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beni-Suef University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beni-Suef University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To Prevent Chemotherapy Induced Ovarian Failure with the gonadotropin-releasing hormone&#xD;
      Agonist Goserelin in Young female Lymphoma Cancer patients Receiving Chemotherapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design:&#xD;
&#xD;
      Study will be prospective interventional simple randomized control parallel open label Arms&#xD;
      and Interventions Arm 1: Goserelin plus standard chemotherapy Goserelin will be given as a&#xD;
      3.6 mg subcutaneous injection in the abdominal wall every 4 weeks (28 ± 3 days) plus standard&#xD;
      chemotherapy at start of regimen for 3 months (26) Arm 2 (control Arm): Standard chemotherapy&#xD;
      Patients will take only standard chemotherapy for 3 months Setting: oncology department Beni&#xD;
      Suef university hospital Sample size: 20-30 patients (based on the results from the&#xD;
      literature and to ensure a power of 80% and a type I error probability of 5%. we calculate&#xD;
      Effect size Primary Outcome Measures&#xD;
&#xD;
      Evaluating ovarian function by: at the start of treatment and after 3 cycles chemotherapy&#xD;
      treatment and at end of 6 cycles chemotherapy through:&#xD;
&#xD;
        -  FSH level (follicle-stimulating hormone (FSH))&#xD;
&#xD;
        -  Estradiol level&#xD;
&#xD;
      Secondary Outcome Measures:&#xD;
&#xD;
        -  Overall All Response determined by tumor assessments from radiological tests including&#xD;
           one of the following (computed tomography scan, Magnetic resonance imaging&#xD;
           Positron-emission tomography or physical examinations according RECIL 2017 criteria.&#xD;
&#xD;
        -  Adverse events (Sweating, Hot flushes, vaginal bleeding, vaginal dryness. Headaches)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Actual">June 1, 2020</completion_date>
  <primary_completion_date type="Actual">December 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Arm 1: Goserelin plus standard chemotherapy Arm 2 (control Arm): Standard chemotherapy</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>prevention premature ovarian failure</measure>
    <time_frame>6 month from start of chemotherapy</time_frame>
    <description>Evaluating ovarian function by FSH,E2 levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall response in lymphoma patients</measure>
    <time_frame>6 month</time_frame>
    <description>Overall response rate determined by tumor assessments from radiological tests including one of the following (computed tomography scan, Magnetic resonance imaging Positron-emission tomography or physical examinations , ( RECIL 2017) The overall response evaluation criteria in lymphoma, criteria categorized patients stable disease,progressive disease ,minor response,partial response,complete response at end of 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADVERSE EFFECTS</measure>
    <time_frame>6 MONTH</time_frame>
    <description>Adverse events (Sweating, Hot flushes, vaginal bleeding, vaginal dryness. Headaches)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Premature Ovarian Failure</condition>
  <arm_group>
    <arm_group_label>Goserelin arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>3.6 mg subcutaneous injection in the abdominal wall every 4 weeks (28 ± 3 days) plus standard chemotherapy at start of regimen for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goserelin</intervention_name>
    <description>chemotherapy+goserelin</description>
    <arm_group_label>Goserelin arm</arm_group_label>
    <other_name>zoladex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>standard chemotherapy</description>
    <arm_group_label>control Arm</arm_group_label>
    <other_name>chemotherapy protocols</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Female lymphoma patients will be included in the study if they meet the following criteria:&#xD;
&#xD;
          1. Confirmed lymphoma cancer radiological and pathological or by clinical evaluation&#xD;
             receiving chemotherapy treatment&#xD;
&#xD;
          2. Normal FSH-level , estradiol level (FSH levels less than 10IU/L at the time of random&#xD;
             assignment)&#xD;
&#xD;
          3. Female Age between 17- 40 years&#xD;
&#xD;
          4. Written informed consent&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        The patients will be excluded from the study if they have the following criteria:&#xD;
&#xD;
          1. Known hypersensitivity reaction to the investigational compounds or incorporated&#xD;
             substances&#xD;
&#xD;
          2. Primary ovarian dysfunction, previous history of amenorrhea &gt;3 months&#xD;
&#xD;
          3. Age &gt; 40&#xD;
&#xD;
          4. Pregnant or lactating patients, prior use of hormonal contraceptives has to be&#xD;
             discontinued before first Goserelin injection&#xD;
&#xD;
          5. patients who are unlikely to comply with trial requirements (eg, confusion,&#xD;
             psychological or mood disturbances ,alcoholism, Vaginitis, vaginal bleeding, cardiac&#xD;
             arrhythmia)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>woman age 17-40 years</gender_description>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Abdullah Elberry Elberry, MD</last_name>
    <role>Study Director</role>
    <affiliation>Assistant Professor of Clinical Pharmacology, Beni-Suef University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raghda Roshdy Sayed Hussein, MD</last_name>
    <role>Study Director</role>
    <affiliation>Lecturer of Clinical pharmacy, Beni-Suef University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ahmed hassan shaaban</last_name>
    <role>Study Director</role>
    <affiliation>Lecturer of Clinical Oncology, Beni-Suef University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beni Suef university</name>
      <address>
        <city>Fayoum</city>
        <state>Mesala</state>
        <zip>11858</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 27, 2020</study_first_submitted>
  <study_first_submitted_qc>September 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2020</study_first_posted>
  <last_update_submitted>September 3, 2020</last_update_submitted>
  <last_update_submitted_qc>September 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beni-Suef University</investigator_affiliation>
    <investigator_full_name>ALshaimaa Ibrahim Rabie</investigator_full_name>
    <investigator_title>assistant lecturer of clinical pharmacy department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Ovarian Insufficiency</mesh_term>
    <mesh_term>Menopause, Premature</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Goserelin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

